# Multi-omics Mass Spectrometry and Biomarker Discovery Core

> **NIH NIH P30** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2022 · $105,644

## Abstract

Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility Shared Resource
ABSTRACT
The Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility (MMSBD) provides Cancer Center
(CC) members with mass spectrometry (MS)-based multi-omics technology to support research on cancer
pathogenesis, cancer biomarkers, novel anti-cancer agents, and diagnostic studies. The multi-omics approaches
provided encompass high-quality MS services for proteomics, peptidomics, glycomics, lipidomics, metabolomics,
and small molecule analyses. Quantitative phosphoproteomics and deep proteomics are new services provided
during the current funding period. The Core offers scientific consultation from project conception and execution
to preparation of manuscripts and grant applications.
Primary Core services are: 1) liquid chromatographic/mass spectrometry (LC/MS); 2) untargeted/targeted
proteomics, including label-free quantitative proteomics as well as stable isotope labeling with isobaric tandem
mass tags or stable isotope labeling of amino acids in culture; 3) identification and quantification of post-
translational modifications; 4) de novo peptide/protein sequence analysis; 5) peptide sequence validation under
GMP conditions (the Core is FDA-registered); 6) lipidomics and metabolomics; 7) biomarker discovery from
clinical samples; 8) assay development and quantification of small molecules, peptides, drugs, and validation of
potential biomarkers; 9) tissue biomarker profiling by MALDI-MS; and 10) tissue imaging mass spectrometry.
The MMSBD is well equipped with cutting-edge major instrumentation including an Orbitrap Fusion Tribrid mass
spectrometer (Thermo); a 6490 Triple Quadrupole mass spectrometer (Agilent); several LC Q-TOF mass
spectrometers (Waters and Agilent), and two MALDI-MS instruments. A second high-end Orbitrap mass
spectrometer (a Fusion Lumos; Thermo) is being purchased to meet increased demands for LC/MS instrument
time. Data analyses are performed on Core-maintained workstations and multi-node computer clusters that
operate both commercial and open source software. Software is constantly updated and MS and metadata are
automatically backed up and stored on several redundant storage units located on and off the main campus.
The core is co-directed by Drs. Markus Kalkum and Robert Hickey, who are both faculty within Beckman
Research Institute. Key decisions affecting the Core are reviewed by an Advisory Committee, composed of CC
members who use the Core’s services. Since the last competitive renewal, the MMSBD contributed to 26
publications by CC members and served 73 investigators, 52 of whom were CC members representing all five
Programs. Of the 52 CC members, 45 (87%) had peer-reviewed funding. Accordingly, the MMSBD provides
accessible, cost-effective, and high-quality multi-omics mass spectrometry and biomarker discovery services to
support the research of the City of Hope Comprehensive Cancer Center.

## Key facts

- **NIH application ID:** 10328528
- **Project number:** 5P30CA033572-39
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** MARKUS KALKUM
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $105,644
- **Award type:** 5
- **Project period:** 1997-08-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10328528

## Citation

> US National Institutes of Health, RePORTER application 10328528, Multi-omics Mass Spectrometry and Biomarker Discovery Core (5P30CA033572-39). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10328528. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*